Palvella Therapeutics PVLA
NASDAQ PVLA
$137.93 -1.07 (-0.77%)
At close: Sep 30, 2026 · 4:00 PM EDT

Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2014)

Updated

Palvella Therapeutics' Debt Ratio came in at 0.06 for FY2014, down 74.4% from 0.23 in FY2013.

Analysis

Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2014) Analysis & Trends

  • Per Business Quant, earlier years put Debt Ratio at 0.23 in FY2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 0.24
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 0.52
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 0.42
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 0.31
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 0.00
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 0.60
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Palvella Therapeutics 2.00 Bn 1.75 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 0.06
Sep 30, 2014 15.79
Jun 30, 2014 0.04
Dec 31, 2013 0.23
API Access

Palvella Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=PVLA&period=max&api_key=YOUR_API_KEY